$GILD Recent Headlines 10 S&P 500 companies growing

New Post Public Reply Private Reply Replies (0) Message Board

Aug 20, 2014 at 10:24 AM

$GILD Recent Headlines

10 S&P 500 companies growing faster than their rivals 3:29 a.m. Today - Philip van Doorn
10 stocks enjoying the biggest increases in earnings estimates 7:27 p.m. Aug. 12, 2014 - Philip van Doorn
Gilead offers to sell Hepatitis C drug in India at 99% off U.S. prices 4:17 p.m. Aug. 8, 2014 - blogs.marketwatch.com
Gilead says EU Committee to recommend approval of leukemia drug 7:32 a.m. July 25, 2014 - Ciara Linnane
Gilead says EU Committee to recommend approval of leukemia drug 7:26 a.m. July 25, 2014 - Ciara Linnane
S&P 500 ekes out another record close: stock market live blog recap 4:03 p.m. July 24, 2014 - blogs.marketwatch.com
Facebook surges to record; SodaStream bubbles higher 1:23 p.m. July 24, 2014 - Tom Bemis
Biotechs beat estimates, but the Street wants more 11:44 a.m. July 24, 2014 - blogs.marketwatch.com
Gilead trounces earnings views, but shares don't feel the after-hours love 5:39 p.m. July 23, 2014 - blogs.marketwatch.com
Updates, advisories and surprises 5:31 p.m. July 23, 2014 - MarketWatch
Facebook rallies in after hours as results top outlook 4:58 p.m. July 23, 2014 - Sue Chang
Biogen results crush consensus 4:55 p.m. July 23, 2014 - The Trading Deck
Gilead trounces estimates on strong Sovaldi sales 4:19 p.m. July 23, 2014 - MarketWatch.com
Gilead trounces estimates for earnings, sales, Sovaldi 4:17 p.m. July 23, 2014 - Russ Britt
Gilead Sovaldi sales reach $3.48B, ahead of $2.87B view 4:10 p.m. July 23, 2014 - Russ Britt
Gilead's $6.53B in revs. beats $5.85B estimate 4:10 p.m. July 23, 2014 - Russ Britt
Gilead adj. earns are $2.36/share vs. view of $1.79 4:09 p.m. July 23, 2014 - Russ Britt
Gilead revs. $6.5 billion vs. year-ago $2.77 billion 4:08 p.m. July 23, 2014 - Russ Britt
Gilead Q2 net is $2.20 vs. year-ago 46 cents 4:07 p.m. July 23, 2014 - Russ Britt
4 ways Gilead’s earnings will impact every American 1:30 p.m. July 23, 2014 - Tim Mullaney

The Medical Innovation Threat 7:06 p.m. Aug. 19, 2014 - The Wall Street Journal Interactive Edition
Will Roche (RHHBY) Buy the Remaining Stake in Chugai? - Analyst Blog 5:55 p.m. Aug. 19, 2014 - Zacks.com
Amgen (AMGN) Reports Encouraging Top-Line Data on AMG 416 - Analyst Blog 5:25 p.m. Aug. 19, 2014 - Zacks.com
Pfizer Submits Palbociclib Marketing Application to the FDA - Analyst Blog 4:20 p.m. Aug. 19, 2014 - Zacks.com
Biogen Strengthens MS Portfolio with Plegridy FDA Approval - Analyst Blog 1:20 p.m. Aug. 19, 2014 - Zacks.com
Gilead Beats Apple To $100. Who Will Win Race To $120? 1:09 p.m. Aug. 19, 2014 - Seeking Alpha
PDL BioPharma Misses on Q2 Earnings due to Higher Expenses - Analyst Blog 9:10 a.m. Aug. 19, 2014 - Zacks.com
Celladon Corp. (CLDN) Jumps: Stock Adds 11.3% in Session - Tale of the Tape 8:51 a.m. Aug. 19, 2014 - Zacks.com
A Market-Beating Veteran on 11 Undervalued Stocks 7:46 a.m. Aug. 19, 2014 - Barrons.com
Gilead’s Chart Scores Another Victory Following a Legal One 8:03 p.m. Aug. 18, 2014 - InvestorPlace.com
New Magic Formula Stocks From Joel Greenblatt: CBI, DAL, GILD, MNST, ROST, LUV 5:44 p.m. Aug. 18, 2014 - GuruFocus.com
Achillion Pharmaceuticals Soars on Mid-Stage HCV Study Data - Analyst Blog 4:45 p.m. Aug. 18, 2014 - Zacks.com
Should Achillion Pharma (ACHN) Be In Your Portfolio Now? - Stocks in the News 3:20 p.m. Aug. 18, 2014 - Zacks.com
Roche's Avastin Approved by FDA for Advanced Cervical Cancer - Analyst Blog 2:30 p.m. Aug. 18, 2014 - Zacks.com
Gilead Scores Legal Victory Over Roche for Sovaldi, Shares Up - Analyst Blog 1:34 p.m. Aug. 18, 2014 - Zacks.com
Achillion Pharmaceuticals Up On Buyout Rumors 12:52 p.m. Aug. 18, 2014 - Investors Business Daily
Jazz, Celgene Lead Top 4 Drugmaker Profit Margins 12:46 p.m. Aug. 18, 2014 - Investors Business Daily
Jim Cramer Answers Twitter (TWTR) Questions on Walmart (WMT), Yelp (YELP), Kinder Morgan (KMI) and More 12:40 p.m. Aug. 18, 2014 - TheStreet.com
#PreMarket Primer: Monday, August 18: Jackson Hole Draws Market Attention 6:12 a.m. Aug. 18, 2014 - benzinga.com
'Fast Money' Recap: Getting Defensive in a Volatile World 5:00 a.m. Aug. 16, 2014 - TheStreet.com

Technical Updates, Drug Recommendations, and Upcoming Events - Research Reports on Gilead, Pfizer, AbbVie, Express Scripts and Humana 9:20 a.m. Aug. 19, 2014 - PR Newswire - PRF
Positive Opinion on the Drug, Acquisition, Orphan Drug Designation, Analysis Results, and Financial Results - Research Reports on Gilead, Pfizer, AbbVie, Express Scripts and Tenet Health 9:10 a.m. Aug. 8, 2014 - PR Newswire - PRF
Critical Alerts For Groupon, Gilead Sciences, Ballard Power Systems, GlaxoSmithKline, and Eli Lilly Released By InvestorsObserver 9:31 a.m. Aug. 4, 2014 - PR Newswire - PRF
Complete Response Letter from FDA, Positive Opinion on Drug, Technical Update, Financial Result Release, and Clinical Trial Results - Research Reports on AcelRx, Horizon, Gilead, AbbVie and Exelixis 9:20 a.m. July 31, 2014 - PR Newswire - PRF
Market Momentum on Biotech Stocks -- IsoRay, Neurocrine Biosciences, OPKO Health, Orexigen Therapeutics, and Gilead Sciences 8:40 a.m. July 31, 2014 - PR Newswire - PRF
Theraclone Announces Exclusive Agreement with Gilead Sciences for Broadly Neutralizing HIV Antibodies 8:00 a.m. July 30, 2014 - BusinessWire - BZX
European CHMP Adopts Positive Opinion for Gilead’s Zydelig® (idelalisib) for the Treatment of Chronic Lymphocytic Leukemia and Follicular Lymphoma 7:24 a.m. July 25, 2014 - BusinessWire - BZX
Galectin, Intercept, Others Vying for Lead Drugs in NASH Epidemic 10:03 a.m. July 24, 2014 - ACCESSWIRE
The Medicines Patent Pool (MPP) Broadens Collaboration with Gilead Sciences: Signs Licence for Phase III Medicine Tenofovir Alafenamide (TAF) 12:30 a.m. July 24, 2014 - PR Newswire - PRF
Gilead Announces New Agreement with Medicines Patent Pool for Access to Medicines in Developing World Countries 12:00 a.m. July 24, 2014 - BusinessWire - BZX
U.S. Food and Drug Administration Approves Gilead’s Zydelig® (idelalisib) for Relapsed Chronic Lymphocytic Leukemia, Follicular Lymphoma and Small Lymphocytic Lymphoma 11:49 a.m. July 23, 2014 - BusinessWire - BZX
Gilead Sciences to Release Second Quarter 2014 Financial Results on Wednesday, July 23, 2014 5:00 p.m. July 16, 2014 - BusinessWire - BZX
Critical Alerts For SunEdison, Twitter, Gilead Sciences, Darden Restaurants, and Blackrock Released By InvestorsObserver 9:31 a.m. July 14, 2014 - PR Newswire - PRF
NDA Submission, Results Release Schedules, FDA Grants and Approvals, and Agreements - Analyst Notes on Gilead, Biogen Idec, Amgen, Illumina and MannKind 5:20 a.m. July 4, 2014 - PR Newswire - PRF
Dividends, Mergers, and Study Results - Analyst Notes on Pfizer, Gilead, Pacira, QLT and Agenus 6:30 a.m. July 1, 2014 - PR Newswire - PRF
AIDSVu Releases New Maps that Depict Impact of HIV in American Cities 9:50 a.m. June 27, 2014 - BusinessWire - BZX
Top White House AIDS Official Visits San Francisco Clinic on National HIV Testing Day 9:00 a.m. June 27, 2014 - PR Newswire - PRF
Gilead Submits New Drug Application to Japan’s Pharmaceutical and Medical Devices Agency for Sofosbuvir for Chronic Hepatitis C 3:01 a.m. June 27, 2014 - BusinessWire - BZX
Biotechnology Equities Technical Notes -- Research on StemCells, Gilead Sciences, Galena Biopharma, and Inovio Pharma 7:10 a.m. June 26, 2014 - PR Newswire - PRF
Gilead Sciences to Present at the Wells Fargo Healthcare Conference on Tuesday, June 17 5:00 p.m. June 16, 2014 - BusinessWire - BZX

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

ELEGOO Slashes Prices up to 54% for 2026 Holiday Deals

ELEGOO's 2026 Holiday Strategy: Deep Discounts Welcome to the world of sharp deals and crafty creations as ELEGOO kicks off its Black Friday and Cyber Monday extravaganza. This time, they're slashing prices by up to 54% on their impressive lineup of 3D printers and captivating accessories. Yeah, it's that time of year when wallets might take a hit, but for a good reason....

Ebix and intentyx Tackle AI Security in Regulated Fields

Ebix Aims to Rein in AI Mischief When you throw AI agents into the mix of regulated businesses like insurers, banks, and healthcare outfits, you get a storm brewing. Now, Ebix and intentyx seem to be donning their capes, aiming to bring clarity with their new SMARE security platform. Fancy name notwithstanding, this isn't about mind games—it's about real, observable...

Tennessee Highlights Alarming COPD Rates This November

Tennessee Turns the Spotlight on COPD Here we are again, looking at Tennessee with its weary lung health woes. Governor Bill Lee's newest proclamation for November as COPD Awareness Month is shining a light on a crisis that's been disproportionately hitting the state harder than a sideswipe from a semi. Why the Proclamation Matters Let's cut through the fog—COPD,...

Military Medical Minds to Converge at MTEC Event in 2027

Ever wonder where the cutting edge of military medicine takes shape? On February 16-17, 2027, Washington, DC becomes the epicenter for just that, as the Medical Technology Enterprise Consortium (MTEC) rolls out its 11th Annual Membership Meeting. A gathering of who's who in the world of military medical innovation, this event is like a high-stakes cocktail of science,...

Blokees Joins 'MIKU WITH YOU 2026' Concert in China

Blokees Partners with Iconic Virtual Star Hatsune Miku There's a new player cozying up in the world of virtual icons, and it's none other than Blokees. If you haven't heard, Blokees just dipped its toes into the buzzing waters of the Hatsune Miku fandom by becoming an official strategic partner at the 'MIKU WITH YOU 2026' concert in Shanghai. You could call this a step up...

Julie Boland's Strategic Move to Deere's Board

Deere & Company Expands Leadership with Boland Out of the blue, Deer & Company (NYSE: DE) decided to shake things up by adding Julie Boland, the former U.S. honcho at Ernst & Young LLP, to their board. Now, when Deere gets a leader with her pedigree, there’s more than a whiff of strategy at play. Let’s unpack why Deere's pulling the trigger on this boardroom shift....

Maya Mobile Wins Best Global Roaming Services 2026

Travelers Speak: Maya Tops Global Roaming It's not every day that you see the travel community collectively high-five a company, but that's precisely what happened with Maya Mobile. These folks just snagged the Best Global Roaming Services title at the TripZilla Excellence Awards 2026, and it's not just fluff—it's voted by travelers. This ain't your typical pat on the...

Camect and 3Si Partnership: Revolutionizing Public Safety

Smarter Surveillance with Camect and 3Si A fresh collaboration is stirring the security pot, straight from Silicon Valley's buzzing tech nest. Camect, the brainiacs behind AI-powered video smarts, are shaking hands with 3Si Security Systems. In plain talk, they're hooking up Camect's sharp-eyed video tech with 3Si's DirectToDispatch™ system. This ain’t some techie...

Target Hospitality Readies for Q3 2026 Earnings Reveal

The Thrill of Earnings Season Every trader worth their salt gets a tingle down the spine come earnings season. There's nothing quite like it—the build-up, the anticipation, the potential payouts. This time, we're zeroing in on Target Hospitality, bearing the ticker NASDAQ: TH. Come November 9, 2026, they're set to unveil what the past quarter had up its sleeve, and like...

Ascletis Showcases Bold Moves in Obesity Drug Arena

If you’ve been watching the developments in the world of obesity treatments, Ascletis Pharma is a name you'd do well not to ignore. With ObesityWeek 2026 on the horizon, these folks aren’t just talking—they’re putting their preclinical cards on the table and they’re noteworthy. Unveiling Future Contenders Ascletis is gearing up to present some of their...